Ortho Regenerative Technologies Reports its Second Quarter 2021 Results
Closed non-brokered and oversubscribed Private Placements for total gross proceeds of $2.6 million, including $353,000 from management and Board members Preclinical results confirmed safety of Ortho-R and statistical significance over standard of...